Cytoskeletal and adhesion protein changes during neoplastic progression of human prostate epithelial cells

Critical Reviews in Oncology/Hematology

Volumn 27, Issue 1, 1998, Pages 69-79

  Prasad, Sarada ^a   Thraves, Peter ^a   Kuettel, Michael ^a   Dritschilo, Anatoly ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ACTIN BINDING PROTEIN; ALPHA ACTININ; ALPHA CATENIN; AZACITIDINE; CATENIN; CELL ADHESION MOLECULE; GAMMA LINOLENIC ACID; GELSOLIN; HERMES ANTIGEN; INTEGRIN; ONCOPROTEIN; PHENYLACETIC ACID DERIVATIVE; RETINOIC ACID DERIVATIVE; TAMOXIFEN; TROPOMYOSIN; UVOMORULIN; VINCULIN; VITAMIN D DERIVATIVE;

ANCHORAGE INDEPENDENT GROWTH; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; ONCOGENE; PROSTATE EPITHELIUM; REVERTANT; REVIEW; TUMOR GROWTH;

EID: 0031802428     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)10031-2     Document Type: Article

References (80)

1. [1] Whittmore AS. Cancer Surv 1994;19-20:309-22.
2. [2] Chirado A. National Cancer Institute Round Table on prostate cancer: future research directions. Cancer Res 1991;51:2498-505.
3. [3] Panel Consensus Statement. Chemoprevention of prostate cancer: guidelines for possible intervention strategies. J Cell Biochem 1992;16H:140-5.
4. [4] Karp JE, Chirado A, Brawley O, Kellof GJ. Prostate cancer prevention: investigational approaches and opportunities. Cancer Res 1996;56:5547-56.
5. [5] Kallioniemi O-P, Visakorpi T. Genetic basis and clonal evolution of human prostate cancer. Adv Cancer Res 1996;68:225-55.
6. [6] Isaacs JT. Prostatic cancer; an overview. Cancer Metastasis Rev 1993;12:1-2.
7. [7] Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM. Molecular biology of prostate cancer progression. Cancer Surv 1995;23:19-32.
8. [8] Cunningham CC. Actin structural proteins in cell motility. Cancer Metastasis Rev 1992;11:69-77.
9. [9] Button E, Shapland C, Lawson D. Actin, its associated proteins and metastasis. Cell Motil Cytoskeleton 1995;30:247-51.
10. [10] Ben-zeev A. Cytoskeletal and adhesion proteins as tumor suppressors. Curr Opin Cell Biol 1997;9:99-108.
11. [11] Giancotti FG, Mainiero F. Integrin-mediated adhesion and signaling in tumorigenesis. Biochem Biophys Acta 1994;1198:47-64.
12. [12] Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochem Biophys Acta 1994;1198:11-26.
13. [13] Bracke ME, van Roy FM, Mareel MM. The E-cadherin/ catenin complex in invasion and metastasis. Curr Top Microbiol Immunol 1996;213:123-61.
14. [14] Webber M, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications part 2. Prostate 1997;30:58-64.
15. [15] Isaacs JT, Isaacs WB, Feitz WF, Scheres J. Establishment and characterization of seven Dunning rat prostate carcinoma cell lines and their use in developing methods for predicting metastatic abilities of prostate cancers. Prostate 1986;9:261-81.
16. [16] Stone KR, et al. Isolation of human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21:274-80.
17. [17] Kaighn ME, Narayan S, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of human prostate carcinoma cell line (PC-3). Invest Urol 1979;17:16-20.
18. [18] Van Steenbrugge GJ, van Uffelen CJC, Bolt J, Schroder FH. The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol 1991;40:207-14.
19. [19] Kaighn EM, Reddel RR, Lechner JF, et al. Transformation of human neonatal prostate epithelial cells by strintium phosphate transfection with a plasmid containing SV40 early region genes. Cancer Res 1989;49:3050-6.
20. [20] Maness PE. Actin structure in fibroblasts: its possible role in transformation and tumorigenesis. In: Dowben R, Shay J, editors. Cell and Muscle Motility. New York: Plenum Press, 1981:335-73.
21. [21] Carley WW, Barak LS, Webb WW. F-actin aggregates in transformed cells. J Cell Biol 1981;90:797-802.
22. [22] Rao JY, Hemstreet III GP, Hurst RE, Bonner RB, Min KW, Jones PL. Cellular F-actin leaves as a marker for cellular transformation: correlation bladder cancer risk. Cancer Res 1991;51:2762-7.
23. [23] Pollard TD, Cooper JA. Actin and actin-binding proteins: a critical evaluation of mechanism and functions. Ann Rev Biochem 1986;55:987-1035.
24. [24] Bretscher A. Microfilament structure and function in the cortical cytoskeleton. Ann Rev Biochem 1991;7:337-74.
25. [25] Prasad SC, Thraves PJ, Dritschilo A, Kuettel MK. Protein expression changes associated with radiation-induced neoplastic progression of human prostate epithelial cells. Electrophoresis 1997;18:629-37.
26. [26] Kuettel MR, Jung M, Thraves P, Prasad SC, Varghese S, Rhim JS, Dritschilo A. Human prostate epithelial cell model system for carcinogenic studies. Rad Oncol Invest 1996;3:340-5.
27. [27] Kuettel MR, Thraves PJ, Jung M, et al. Radiation-induced neoplastic transformation of human prostrate epithelial cells. Cancer Res 1996;56:5-10.
28. [28] Prasad SC, Thraves PJ, Dritscilo A, Rhim JS, and Kuettel MK. Cytoskeletal changes during radiation-induced neoplastic transformation of human prostate epithelial cells. Scanning Microsc, 1997 (in press).
29. [29] Matsumara F, Matsumara YS. Tropomyosin in cell transformation. Cancer Rev 1986;6:21-39.
30. [30] Bhattacharya B, Prasad GL, Valverius EM, Salomon DS, Cooper HL. Tropomyosins of human mammary epithelial cells: consistent defects of expression in mammary carcinoma cell lines. Cancer Res 1990;50:2105-12.
31. [31] Leavitt J, Latter G, Lutomski L, Goldstein D, Burbrck S. Tropomyosin isoform switching in tumorigenic human fibroblasts. Mol Cell Biol 1986;6:2721-6.
32. [32] Jooss K, Muller R. Deregulation of genes encoding microfilament-associated proteins during Fos-induced morphological transformation. Oncogene 1995;10:603-8.
33. [33] Prasad GL, Fuldner RA, Cooper HL. Expression of transduced tropomyosin-1 cDNA suppresses neoplastic growth of cells transformed by the ras oncogene. Proc Natl Acad Sci USA 1993;90:7039-43.
34. [34] Gimona M, Kazzaz JA, Helfman DM. Forced expression of tropomyosin-2 or -3 in v-Ki-ras-transformed fibroblasts results in distinct phenotypic effects. Proc Natl Acad Sci USA 1996;93:9618-23.
35. [35] Matsumara F, Yamashiro S. Caldesmon. Curr Opin Cell Biol 1993;5:70-6.
36. [36] Kumar CC, Mohan S, Chang C, Garrels JI. Cytoskeletal proteins in tumor diagnosis. In: Osborn M, Weber K, editors. Current Communications in Molecular Biology. New York: Cold Spring Harbor, 1989:91-7.
37. [37] Joseph CK, Qureshi SA, Wallace DJ, Foster DA. MARCKS protein is transcriptionally down-regulated in v-src transformed BALB/c 3T3 cells. J Biol Chem 1992;267:1327-30.
38. [38] Yin HL. Gelsolin: calcium and phosphoinositide-regulated actin-modulating protein. Bioassays 1987;7:176-9.
39. [39] Cunningham CC, Stossel TP, Kwaitoski DJ. Enhanced motility in NIH 3T3 fibroblasts that over-express gelsolin. Scinece 1991;251:1233-6.
40. [40] Vandekerckhove J, Bauw G, Vancompernolle K, Honore B, Celis J. Comparative 2-D gel analysis and micro-sequencing identifies gelsolin as one of the most prominent down-regulated markers of transformed human fibroblast and epithelial cells. J Cell Biol 1990;111:95-102.
41. [41] Asch H, Head K, Dong Y, Natoli F, Winston JS, Connolly JL, Asch BB. Widespread loss of gelsolin in breast cancers of humans mice and rats. Cancer Res 1996;56:4841-5.
42. [42] Tanaka M, Mauller L, Ogiso Y, et al. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res 1995;55:3228-32.
43. [43] Benzeev A, Rodriguez F, Gluck U, Salomon D, Geiger B. Changes in adhesion plaque proteins levels regulate cell motility and tumorigenicity. Adv Exp Med Biol 1994;358:147-57.
44. [44] Rodriguez-Fernandez JS, Geiger B, Salomon D, Sabany I, Zoller M, beneev A. Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA. J Cell Biol 1992;119:427-38.
45. [45] Gluck U, Kwaitowski DJ, Benzeev A. Suppression of tumorigenicity in simian virus 40-transformed 3T3 cells transfected with α-actinin cDNA. Proc Natl Acad Sci USA 1993;90:383-7.
46. [46] Gluck U, Benzeev A. Modulation of α-actinin levels affects cell motility and confers tumorigenicity on 3T3 cells. J Cell Sci 1994;107:1773-82.
47. [47] Johnes J, Sugiyam M, Speight PM, Watt PM. Restoration of αvβ5 integrin expression in neoplastic keratinocytes results in increased capacity for terminal differentiation and suppression of anchorage-independent growth. Oncogene 1995;92:7041-5.
48. [48] Zutter MM, Santoro SA, Staatz WD, Tsung YL. Reexpression of the α2β1 integrin expression abrogates the malignant phenotype of breast carcinoma cells. Proc Natl Acd Sci USA 1995;92:7411-5.
49. [49] Coffey D. Prostate cancer metastasis: talking the walk. Nat Med 1995;2:1305-6.
50. [50] Bao L, Loda M, Janmey PA, Stewart R, Apte BA, Zetter B. Thymosin b15: a novel regulator of tumor cell motility up-regulated in metastatic prostate cancer. Nat Med 1996;2:1322-8.
51. [51] Dedhar S. Integrin mediated signal tranduction on oncogenesis: an overview. Cancer Metastasis Rev 1995;14:165-72.
52. [52] Mohler JL. Cell motility and prostatic carcinoma metastases. Cancer Metastasis Rev 1993;12:53-67.
53. [53] Cress AE, Rabinowitz I, Zhu W, Nagle RB. The α6β1 and α6β4 integrins in human prostate cancer progression. Cancer Metastasis Rev 1995;14:219-28.
54. [54] Knox DJ, Cress AE, Clark V, Manriquez L, Affinito K, Dalkin B, Nagle RB. Differential expression of extra-cellular matrix molecules and the α6-integrins in the normal and neoplastic prostate. Am J Pathol 1994;145:167-74.
55. FAK) expression, activation and association with paxillin and in human metastatic prostate carcinoma. Int J Cancer 1996;68:164-71.
56. FAK both by cellular adhesion and oncogenic transformation. Nature 1992;358:690-2.
57. [57] Pierceall WE, Woodara AS, Morrow JS, Rimm D, Fearon ER. Frequent alterations in E-cadherin and α-and β-catenin expression in human breast cancer cell lines. Oncogene 1995;11:1319-26.
58. [58] Graff JR, Herman JG, Lapidus RG, et al. E-cadherin expression is silenced by DNA hyper-methylation in human breast and prostate carcinomas. Cancer Res 1995;55:5195-9.
59. [59] Ewing CM, Ru N, Morton RA, et al. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of α-catenin and restoration of E-cadherin function. Cancer Res 1995;55:4813-7.
60. [60] Hulsken J, Birchmeier W, Bohrens J. E-Cadherin and APC compete for the interaction with β-catenin and the cytoskeleton. J Cell Biol 1994;127:2061-9.
61. [61] Simcha I, Geiger B, Lavenberg S, Salomon D, Benzeev A. Suppression of tumorigenicity by plakoglobin: an augmenting effect of N-cadherin. J Cell Biol 1996;133:199-209.
62. [62] Kleinerman DI, Troncoso P, Lin SH, et al. Consistent expression of an epithelail cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: Implications as tumor suppressor. Cancer Res 1995;55:1215-20.
63. [63] Welsh CF, Zhu D, Bourguignon LYW. Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells. J Cell Physiol 1995;164:605-12.
64. [64] Gao AC, Lou W, Dong JT, Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997;57:846-9.
65. [65] Prendergast GC, Gibbs JR. Pathways to ras function: connections to the actin cytoskeleton. Adv Cancer Res 1993;62:19-63.
66. [66] Kanai Y, Ochiai A, Shibata T, Oyama T, Ushijima S, Akimoto S, Hirohashi S. C-erb-2 gene product directly associates with β-catenin and plakoglobin. Biochm Biophys Res Commun 1995;208:1067-72.
67. [67] Noda M. Mechanisms of reversion. FASEB J 1993;7:834-46.
68. [68] Puck TT, Krystosek A. Reverse transformation, genome exposure, and cancer. Adv Cancer Res 1996;68:225-55.
69. [69] Prendergast GC, Davide JP, deSolmes SJ, et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 1994;14:4193-202.
70. [70] Dahiya R, Park HD, Cusick J, Vessela RL, Fournier G, Narayan P. Inhibiiton of tumorigenic potential and prostate-specific antigen expression in LNCAP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer 1994;59:126-32.
71. [71] Esquenet M, Swinnen JV, Heyns W, Verhoven G. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1-α-25-dihydroxy-cholecalciferol, all-trans-retinoic acid, 9-cis-retinoic acid, and phenylacetate. Prostate 1996;28:182-94.
72. [72] Lucia MS, Anzano MA, Slayter MV, Anver MR, et al. Chemopreventive activity of tamoxifen, retinamide, and the vitamin D analogue for androgen promoted carcinoma of the rat seminal vesicle and prostate. Cancer Res 1995;55:5621-7.
73. [73] Pienta KJ, Nguyen NM, Lehr JE. Treatment of prostate cancer in the rat with the synthetic retinoid finretinide. Cancer Res 1993;53:224-6.
74. [74] Giovannuci E, Ascerio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995;87:1767-76.
75. [75] Vermeulen SJ, Bruyneel EA, van Roy FM, Mareel MM, Bracke ME. Activation of the E-cadherin/catenin complex in human MCF-7 breast cancer cells by all-trans-retinoic acid. Br J Cancer 1995;72:1447-53.
76. [76] Byers S, Pishivan M, Crockett C, et al. Retinoids increase cell-cell adhesion strength, β-catenin protein stability, and localization to the cell membrane in a breast cancer cell line: a role for serine kinase activity. Endocrinology 1996;137:3265-73.
77. [77] Stellmach V, Leask A, Fuchs E. Retinoid-mediated transcriptional regulation of keratin genes in human epidermal and squamous cell carcinoma cells. Proc Natl Acad Sci USA 1991;88:4582-6.
78. [78] Crowe DL. Retinoic acid mediates post-transcriptional regulation of keratin 19 mRNA levels. J Cell Sci 1993;106:183-8.
79. [79] Samid D, Shack S, Myers CE. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 1993;91:2288-95.
80. [80] Jiang WG, Hiscox S, Hallet MB, Horrobin DF, Mansel RE, Puntis MC. Regulation of the expression of E-cadherin on human cancer cells by γ-linolenic acid (GLA). Cancer Res 1995;55:5043-8.